Derrick E Fouts
Overview
Explore the profile of Derrick E Fouts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
8227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mobley H, Anderson M, Moricz B, Severin G, Holmes C, Ottosen E, et al.
PLoS Pathog
. 2024 Aug;
20(8):e1012495.
PMID: 39178317
There is a critical gap in knowledge about how Gram-negative bacterial pathogens, using survival strategies developed for other niches, cause lethal bacteremia. Facultative anaerobic species of the Enterobacterales order are...
2.
Poteete O, Cox P, Ruffin F, Sutton G, Brinkac L, Clarke T, et al.
PLoS One
. 2024 Jul;
19(7):e0307968.
PMID: 39074102
The innate immune system eliminates bloodstream pathogens such as Escherichia coli in part through complement protein deposition and subsequent bacterial death (i.e., "serum killing"). Some E. coli strains have developed...
3.
Viebahn G, Hartmann P, Lang S, Demir M, Zhang X, Fouts D, et al.
Gut Microbes
. 2024 Feb;
16(1):2307586.
PMID: 38298161
The fungal microbiota plays an important role in the pathogenesis of alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). In this study, we aimed to compare changes of...
4.
Boonyasiri A, Brinkac L, Jauneikaite E, White R, Greco C, Seenama C, et al.
BMC Infect Dis
. 2023 Aug;
23(1):556.
PMID: 37641085
Background: Colistin is one of the last resort therapeutic options for treating carbapenemase-producing Enterobacterales, which are resistant to a broad range of beta-lactam antibiotics. However, the increased use of colistin...
5.
Brumwell A, Sutton G, Lantos P, Hoffman K, Ruffin F, Brinkac L, et al.
J Clin Microbiol
. 2023 Jun;
61(7):e0019923.
PMID: 37338371
Escherichia coli sequence type 131 (ST131) is a globally dominant multidrug-resistant clone, although its clinical impact on patients with bloodstream infection (BSI) is incompletely understood. This study aims to further...
6.
Zeng S, Hartmann P, Park M, Duan Y, Lang S, Llorente C, et al.
Hepatol Commun
. 2023 Jan;
7(2):e0029.
PMID: 36706195
Chronic alcohol consumption is associated with intestinal fungal dysbiosis, yet we understand little about how alterations of intestinal fungi (mycobiota) contribute to the pathogenesis of alcohol-associated liver disease. By reanalyzing...
7.
Hsu C, Lang S, Demir M, Fouts D, Starkel P, Schnabl B
Hepatology
. 2023 Jan;
77(6):2073-2083.
PMID: 36631002
Background And Aims: The prevalence of alcohol use disorder (AUD) and metabolic dysfunction-associated fatty liver disease (MAFLD) are increasing worldwide, leading to the increasing likelihood of both etiologies contributing to...
8.
Filippov A, Su W, Sergueev K, Kevorkian R, Snesrud E, Srijan A, et al.
Antibiotics (Basel)
. 2022 Nov;
11(11).
PMID: 36421303
Shigellosis is a leading global cause of diarrheal disease and travelers' diarrhea now being complicated by the dissemination of antibiotic resistance, necessitating the development of alternative antibacterials such as therapeutic...
9.
Mojica M, Humphries R, LiPuma J, Mathers A, Rao G, Shelburne S, et al.
JAC Antimicrob Resist
. 2022 May;
4(3):dlac040.
PMID: 35529051
is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by a great clinical challenge. Clinical management is further...
10.
Mencke J, He Y, Filippov A, Nikolich M, Belew A, Fouts D, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458437
is an emerging opportunistic Gram-negative pathogen with reports of increasing antibiotic resistance. Pan-drug resistant (PDR) infections are a growing concern, demonstrating a need for the development of alternative treatment options...